

# REIMBURSEMENT GUIDE

## **IMPORTANT SAFETY INFORMATION**

#### Indication

TRILURON® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g. acetaminophen).

## **Important Safety Information**

Do not administer TRILURON® to patients with known hypersensitivity to hyaluronate preparations. Intraarticular injections are contraindicated in cases of past and present infections or skin diseases in the area of the injection site to reduce the potential for developing septic arthritis. The safety and effectiveness of TRILURON® has not been tested in pregnant women, nursing mothers or children. See package insert for full prescribing information including adverse events, warnings, precautions, and side effects at www.TRILURON.com.

## Rx Only

See package insert for full prescribing information including indications, contraindications, warnings, precautions, and adverse events.

Please see full Prescribing Information at www.TRILURON.com.



The TRILURON® Support Hotline does not file claims or appeal claims for callers, nor can it guarantee that you will be successful in obtaining reimbursement. Third-party payment for medical products and services is affected by numerous factors, not all of which can be anticipated or resolved by the Hotline.

TRILURON® is a trademark of FIDIA FARMACEUTICI S.P.A., Abano Terme, Italy. ©2019 FIDIA PHARMA USA INC., Florham Park, NJ 07932, a wholly owned subsidiary of FIDIA FARMACEUTICI S.P.A. FID779-11.2019.



## **INTRODUCTION**

## **Description and Indication**

TRILURON® is a viscous solution consisting of a high molecular weight (500,000–730,000 daltons) fraction of purified sodium hyaluronate (Hyalectin®) in buffered physiological sodium chloride, having a pH of 6.8-7.5. The sodium hyaluronate is extracted from rooster combs. Hyaluronic acid is a natural complex sugar of the glycosaminoglycan family and is a long-chain polymer containing repeating disaccharide units of Naglucuronate-Nacetylglucosamine.

TRILURON® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g. acetaminophen).

## Please see full Prescribing Information at www.TRILURON.com.

## **Dosage and Administration**

TRILURON® is supplied as a sterile, non-pyrogenic solution in 2 mL prefilled syringes. TRILURON® is administered by intra-articular injection. A treatment cycle consists of three injections given at weekly intervals. Subcutaneous lidocaine or similar local anesthetic may be recommended prior to injection of TRILURON®.

## Using the TRILURON® Reimbursement Guide

This guide is designed to serve healthcare professionals as a reference for general coding and claims information related to TRILURON®. There are many factors that affect how payers will cover and pay for TRILURON®, including the site of service where it is administered, what type of health insurance the patient has, and the type of benefits the payer offers. This guide contains the following information:

Coding for TRILURON® by site of service, including coding for the diagnosis and administration procedure

TRILURON® Support Hotline services and contact information

**Prior Authorization checklist** 

Sample claim forms that illustrate the key components that may be required by a payer when completing a claim for TRILURON®

Tips for submitting clean claims and strategies to appeal denied claims



## **DISCLAIMER**

Information described in the TRILURON® Reimbursement Guide is intended solely for use as a resource tool to assist physician office, hospital outpatient, and ambulatory surgical center billing staff regarding reimbursement issues. Any determination regarding if and how to seek reimbursement should be made only by the appropriate members of the staff, in consultation with the physician, and in consideration of the procedure performed or therapy provided to a specific patient. FIDIA FARMACEUTICIS.P.A/FIDIA PHARMA USA INC. does not recommend or endorse the use of any particular diagnosis or procedure code(s) and makes no determination if or how reimbursement may be available. Of important note, reimbursement codes and payment, as well as health policy and legislation, are subject to continual change; information contained in this version of the TRILURON® Reimbursement Guide is current as of October 2019.

Information provided in the TRILURON® Reimbursement Guide is for your guidance only. The *TRILURON® Support Hotline* does not file or appeal claims for callers, nor can it guarantee reimbursement by third-party payers. For details on the specific services provided by the *TRILURON® Support Hotline*, please see the following section of the TRILURON® Reimbursement Guide. Reimbursement specialists at the *TRILURON® Support Hotline* are available to assist you with questions related to reimbursement support and access services for therapy with TRILURON® at 1-866-749-2542, Option 2, Monday through Friday, from 9:00 AM to 8:00 PM ET.



## **OVERVIEW OF REIMBURSEMENT SUPPORT PROGRAM**

#### TRILURON® Support Hotline

Coverage and coding for TRILURON® (sodium hyaluronate) may vary depending on the patient's type of health insurance and the site of service where the product is administered (ie, physician office, hospital outpatient department, or ambulatory surgical center). It will be important to conduct a benefit investigation for each patient in order to verify the following:

Coverage and utilization restrictions, such as Prior Authorization, for TRILURON®

Patient copayment or coinsurance for TRILURON® and administration services

**Coding for TRILURON®** 

Provider's network status with plan

Upon request, the *TRILURON® Support Hotline* will provide Prior Authorization support by submitting, if possible, any of the information available for a verbal Prior Authorization if the payer will accept it from the *Hotline*.

TRILURON® Support Hotline offers comprehensive reimbursement assistance to practices, ambulatory surgical centers, and hospital providers. Reimbursement counselors are available to support healthcare professionals with questions and the following support services:



Patient-specific benefit verification for medical and specialty pharmacy benefits



Coding and billing support



**Comprehensive Prior Authorization support** 



Alternative coverage research



**Claims management** 



**Appeals assistance** 



Specialty pharmacy triage, upon request



## OVERVIEW OF REIMBURSEMENT SUPPORT PROGRAM (CONT.)

TRILURON® Support Hotline provides timely information to healthcare professionals in order to expedite patient access to care. In fact, most reimbursement research requests can be completed in 1 to 2 business days from the time complete information is submitted to the Hotline.

It is helpful to have the following information available when calling the *Hotline* to speak with a reimbursement counselor:



Physician's name, address, phone number, and provider number (NPI, TID, etc)



Policy identification and group numbers



Patient's name, date of birth, address, and Social Security number



**Diagnosis** 



Insurance company name, phone number, and fax number



Site of care



Name of policy holder



Office contact name and phone number

In addition to reimbursement assistance, the *TRILURON®* Support Hotline will work with you and your patients to provide additional resources that may include the following:

- Patient case management services
- Product ordering management

In order to access services available through the *TRILURON® Support Hotline*, healthcare professionals and their patients are asked to fill out and sign a benefit verification request form. You can obtain the form by contacting the *TRILURON® Support Hotline*, accessing it on the <a href="www.TRILURON.com">www.TRILURON.com</a> website, or requesting one from your Fidia sales representative.





# CODING FOR TRILURON® (sodium hyaluronate) AND ASSOCIATED SERVICES

## Coding for TRILURON®

Most payers recognize Healthcare Common Procedure Coding System (HCPCS) Level II national codes to identify and report products (drugs and medical devices), supplies, and services not included in the Current Procedural Terminology (CPT) code.

For TRILURON®, payers accept the following HCPCS code:

HCPCS Code	Description	Billing Units	Site of Service	Claim Form (Location)	Payer Type
	Hyaluronan or	20	Physician Office	CMS-1500 (Box 24D)	
J7332	derivative, TRILURON® or intra-articular	(1 mg = 1 billing unit  Each syringe =  20 billing units)	Hospital outpatient	CMS-1450 (Field 44)	All
	injection 1 mg	0,	Ambulatory surgical center	CMS-1450 (Field 44)	

TRILURON® is supplied in a single-use syringe containing 2 mL of TRILURON®

- Each mL has 10 mg of sodium hyaluronate
- 2 mL has 20 mg of sodium hyaluronate
- TRILURON® administration does not vary by patient
  - Uniform administration for all patients

Medicare reimburses TRILURON® at WAC+6%

Source: Medicare Claims Processing Manual Chapter 17 (Rev. 4384, 08-30-19) Transmittal 20.1.3 <a href="https://www.cms.gov/Regulations-and-Guidance/Guidance/Guidance/Manuals/Downloads/clm104c17.pdf">https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c17.pdf</a>. Contact private payers or consult contracts for their reimbursement amounts.

## Catalog Number (also known as the NHRIC)

For devices such as TRILURON®, the manufacturer adopts a unique, 3-segment catalog number sometimes referred to as the national-related items code (NHRIC). Proper billing, especially to Medicare, Medicaid, or via electronic data interchange, requires the catalog number to be submitted in the 11-digit numeric 5-4-2 format (e.g. 89122-0879-01). Do not use hyphens when entering the actual data on your claim. For example:

TRILURON® 11-digit Example	Reporting on CMS Claim Forms
89122-0879-01	89122087901



## **Coding for Administration Services**

CPT codes are used to identify professional services (eg, administration procedure) provided in the physician office.

CPT Code Description	
20610	Arthrocentesis, aspiration, and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); without ultrasound guidance
Arthrocentesis, aspiration, and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); with ultrasound guidance	

Modifier	Modifier Description		
RT	Right side (used to identify procedures performed on the right side of the body)		
LT	Left side (used to identify procedures performed on the left side of the body)		
50	Bilateral procedure		
EJ	Indicates subsequent injections of a series. Do not use for first injection of each series.		

## **ICD-10-CM Diagnosis Codes**

International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) diagnosis codes are used to report diseases and conditions. ICD-10-CM diagnosis codes identify why a patient needs treatment by documenting the medical necessity for prescribing TRILURON®. Coding to the highest level of specificity may expedite the claims adjudication process. The following ICD-10-CM diagnosis codes may be appropriate to describe patients with OA of the knee.

ICD-10-CM	Description		
M17.0	Bilateral primary osteoarthritis of knee		
M17.10	Unilateral primary osteoarthritis, unspecified knee		
M17.11	Unilateral primary osteoarthritis, right knee		
M17.12	Unilateral primary osteoarthritis, left knee		
M17.2	Bilateral post-traumatic osteoarthritis of knee		
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee		
M17.31	Unilateral post-traumatic osteoarthritis, right knee		
M17.32	Unilateral post-traumatic osteoarthritis, left knee		
M17.4	Other bilateral secondary osteoarthritis of knee		
M17.5	Other unilateral secondary osteoarthritis of knee		
M17.9	Osteoarthritis of knee, unspecified		

Coding for TRILURON® may vary by payer type and plan type (ie, Medicare, private payer, Medicaid). Upon request, the *TRILURON® Support Hotline* will conduct benefit verifications that provide coverage and coding information that is specific to your patient's health insurance coverage. The *Hotline* program is available Monday through Friday from 9:00 AM to 8:00 PM ET at 1-866-749-2542, Option 2.



# MEDICARE NATIONAL AVERAGE REIMBURSEMENT RATE INFORMATION\*

Site of Service	CPT Code	Website for Look-up	
Physician	20610	https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PFSlookup/index.htm	
Office	20611		
Hospital	20610	https://www.cms.gov/Medicare/Medicare-Fee-for-Service-	
Outpatient	20611	Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates.html	
Ambulatory	20610	https://www.cms.gov/Medicare/Medicare-Fee-for-Service-	
Surgical Center	20611	Payment/ASCPayment/11 Addenda Updates.html	

<sup>\*</sup>Reimbursement rates for CPT codes vary by geography; consult the CMS website for regional rates applicable to the practice or contact the local Medicare Administrative Contractor for regional rates.



## PRIOR AUTHORIZATION CHECKLIST

The TRILURON® Support Hotline is happy to assist you with obtaining information for prior authorization (PA) for TRILURON® (sodium hyaluronate). However, if your office chooses to obtain this information without the assistance of the TRILURON® Support Hotline, please use the checklist below to ensure that you are obtaining the information you need from your patient's insurer.

Patient Name:		DOB:		
Payer Name:	Phone #:		Date:	
Questions to Ask		Ans	wers	
Is a PA required?	☐ Yes		□No	
What information is needed by the insurer for the PA?	□ Diagnosis □ P □ Other:	revious therapy 🗆 🤇	Chart notes	
Does the patient need to have a failure, contraindication, or intolerance to the following treatment options?	□ Non-pharmacologic (e.g. exercise, physical therapy, weight lose if overweight) □ Intra-articular corticosteroids □ Non-steroidal anti-inflammatory medications (e.g. ibuprofen) □ Non-narcotic analgesics (e.g. acetaminophen)			
Does the patient need to have documented symptomatic osteoarthritis of the knee?	□Yes		□No	
Does the patient need to have tried any	☐ Yes (if yes, complete below)		□No	
other medications for the condition?	Medication/Therapy:		Duration of Therapy:	
Does the insurer have a specific PA form?	☐ Yes ☐ No			
If the insurer has a specific PA form, how is	Online	Insurer provider po	rtal	Fax
that form obtained (via website, provider portal address, and/or fax number)?				
How is the PA submitted to the insurer?	Phone	Insurer provider portal Fax		Fax
(obtain phone, fax, and/or portal address)				
Will the insurer provide a PA number to	□Yes		□No	
include on the claim form?	PA Number:			
How long does it take the insurer to review the PA request?				
Is there a required specialty pharmacy for	☐ Yes (if yes, complete below) ☐ No			
TRILURON® acquisition?	Specialty pharmacy:			
If a specialty pharmacy provides TRILURON®, who obtains the PA?	□ Specialty pharmo	асу	☐ Provider office	



How long is the PA valid for TRILURON®?

**NEED ASSISTANCE? Contact the TRILURON® Support Hotline.** Call 1-866-749-2542, Option 2, between 9 AM and 8 PM ET, Monday through Friday.




## **SAMPLE CMS-1500 CLAIM FORM FOR TRILURON®**

(SODIUM HYALURONATE)

200 A			
EALTH INSURANCE CLAIM FORM PROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12			
PICA		PICA	
MEDICARE         MEDICAID         TRICARE         CHAMPY           (Medicare#)         (Medicaid#)         (ID#/DoD#)         (Member)	— HEALTH PLAN — BLK LUNG —	1a. INSURED'S I.D. NUMBER (For Program in Item 1)	
This document is	provided for your gui	dance only. Please call	
· · · · · · · · · · · · · · · · · · ·		5-749-2542, select option	
2 to verify coding	g and claim informati	on for specific payers.	
P CODE TELEPHONE (Include Area Code)		ZIP CODE TELEPHONE (Include Area Code)	
DTHER INSURED'S NAME (Last Name, First Name, Middle Initial)	10, IS PATIENT'S CONDITION RELATED TO:	11. INSURED'S POLICY GROUP OR FECA NUMBER	
OTHER INSURED'S POLICY OR GROUP NUMBER	a, EMPLOYMENT? (Current or Previous)	a. INSURED'S DATE OF BIRTH SEX	
	YES NO	a. INSUREDS DATE OF BIRTH  MM   DD   YY  M   F   F	
ESERVED FOR NUCC USE	b, AUTO ACCIDENT? PLACE (State)	b. OTHER CLAIM ID (Designated by NUCC)	
ESERVED FOR NUCC USE	c, OTHER ACCIDENT?	c. INSURANCE PLAN NAME OR PROGRAM NAME	
SURANCE PLAN NAME OR PROGRAM NAME	YES NO  10d. CLAIM CODES (Designated by NUCC)	d. IS THERE ANOTHER HEALTH BENEFIT PLAN?	
READ BACK OF FORM BEFORE		YES NO If yes, complete items 9, 9a, and 9d.	
ATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I popocess this claim. I also request payment of government I elow.  For ICE	21 ICD Indicator: Identify the type of diagnosis code used; (enter a "0" D-10-CM)	, ces described below.	
MATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) 15.	OTHER DATE MM I DD VV	16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION MM	
QUAL, QUAL QUAL QUAL QUAL QUAL QUAL QUAL QUAL	AL.	FROM TO TO	
171		Find From Find Find From Find From Find From From From From From From From From	
ADDITIONAL CLAIM INFORMATION (Designated by NUCC)		20. OUTSIDE LAB? number as obtained prior to	
DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to sen	rice line below (24E) ICD Ind. 0	22. RESUBMISSION services rendered	
M17.12	D. L	23. PRIOR AUTHORIZATION NUMBER	
J. [ K. ]	L, L	Box 24G Units: Ent	
	EDURES, SERVICES, OR SUPPLIES  ain Unusual Circumstances)  DIAGNOSIS  POS   MODIFIER  POINTER	F. GAYS DAYS OR FEMALE SCHARGES SCHARGES DAYS OR FEMALE SCHARGES DAYS OR FEMALE SCHARGES DAYS OF THE SCHARGES DAYS	
land land		number of units of	
DD   YY   MM   DD   YY   11	A	xx xx 20 service (e.g. <b>J/332</b> is per 1 mg, for a syring	
DD YY MM DD YY 11 20610	- LT A	xx xx 1 of TRILURON® that is	
1 1 1 1 1 1		20 units)	
Box 24D Procedures/Services/Supp		MDI	
Enter the appropriate CPT/HPCS codes - J-Code: 7332 for TRILURON®, per	_	21 Diagnosis: Enter the appropriate diagnosis	
- Administration: e.g. <b>20610</b> , arthrocen	0	e (e.g. ICD-10-CM: <b>M17.12</b> , unilateral primary	
and/or injection, major joint or bursa, w	rithout oste	oarthritis, left knee)	
<ul> <li>ultrasound guidance</li> <li>Modifier: e.g. LT for left knee</li> </ul>	EPT ASSIGI ovt. daims, sec	e: Other diagnosis codes may be applicable	
- Modifier, e.g. Li for left knee	TION	Other diagnosis codes may be applicable	
certify that the statements on the reverse			
apply to this bill and are made a part thereof.)			
apply to this bill and are made a part thereof.)		a. NDI b.	

## SAMPLE CMS-1450 (UB-04) CLAIM FORM FOR TRILURON® (SODIUM HYALURONATE) IN HOSPITAL OUTPATIENT SETTING



## TIPS FOR CLEAN CLAIMS SUBMISSION

The most common reasons for denied claims include:

Use of incorrect codes on claim

Incorrect number of units reported

Omission of letter of medical necessity

Missing or incorrect information on claim form (e.g. misspelled patient name)

Failure to obtain a PA before initiating treatment or failure to include the PA approval number on the claim form

Since payers may have different guidelines for coding and claims filing, it is important to check with individual plans to research claims-submission requirements.

Not all payers will be familiar with TRILURON® (sodium hyaluronate) since it is a newer product and billed with its own unique HCPCS code. Payers may need more information about a product if they are unfamiliar with it and may request additional information about the patient's treatment or diagnosis in order to determine whether a treatment is medically necessary. A letter of medical necessity may help to explain why TRILURON® is medically necessary for the patient's treatment. Claims for TRILURON® may include supporting materials such as:



**Customized letter of medical necessity** 



**Package insert** 



Invoice



Patient medical history



**FDA** approvalletter



**Prior therapies** 



**Chart notes** 



## **Strategies to Appeal Denied Claims**

If a claim for TRILURON® (sodium hyaluronate) is improperly reimbursed or denied, you may consider submitting an appeal. The following list provides some tips for appealing denied claims:

Review the explanation of benefits (EOB) to determine the reason for the denial

If additional information is requested, submit the necessary documentation immediately

Submit a corrected claim if the denial was due to a technical billing error (e.g. missing additional information associated with miscellaneous codes, incorrect patient identification number, missing diagnosis)

Verify the appeals process with the payer

- Is there a particular form that must be completed?
- Can the appeal be conducted over the phone or must it be in writing?
- To whom should the appeal be directed?
- What information must be included with the appeal (e.g. copy of original claim, EOB, supporting documentation)?
- How long does the appeals process usually take?
- How will the payer communicate the appeal decision?

Review appeal request for accuracy, including patient identification numbers, coding, and requested information

Request that a specialist who is familiar with TRILURON® review the claim for medical necessity. It is preferable to have the claim reviewed by a specialist who is presently treating patients with TRILURON®

File claims appeal as soon as possible and within filing time limits

Reconcile claims appeal responses promptly and thoroughly to ensure appeals have been processed appropriately

Record appeals result (e.g. payment amount or if further action is required)

If you have already submitted a letter of medical necessity, you should include a letter of appeal indicating why the product and/or the procedure should be covered and paid by the payer

Additionally, you should include a copy of the original claim and denial notification, the patient's complete medical history, the physician's plan for continuing treatment and relevant journal articles supporting the use of TRILURON®

If this second claim submission is denied, it may be necessary to contact the payer's medical or claims director. Often a claim denial is reversed upon a director's review of an accurate and complete denial appeal request

For assistance in researching a payer's appeal process and preparing a denial appeal, please call the *TRILURON® Support Hotline* at 1-866-749-2542, Option 2. A reimbursement counselor can assist you in developing an appeal strategy. We will work with your practice or patient to assist in an appeal as most appropriate.

